Venaxis expects APPY1 approval following positive trial; shares soar

|By:, SA News Editor

Venaxis' (APPY) APPY1 Test for identifying patients who are at low risk of appendicitis performed well in a pivotal trial, with sensitivity and negative predictive value results surpassing those in a pilot study.

Venaxis believes that the data is enough to receive FDA approval, and the company intends to file a 510(k) application in the next few weeks.

Shares surge 29% premarket. (PR)